ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly endocrinology therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2019] ($M)
Form 10-K Note 2 (legacy Endocrinology grouping)
Latest, FY2017
10,085
Period ended Dec 31, 2017
Change on a year earlier
+24.8%
8,083 in FY2016
History
7 years
Since FY2011
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Endocrinology therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2019] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2017 | Dec 31, 2017 | 10,085 | +24.8% | Form 10-K (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | 8,083 | +14.9% | Form 10-K (filed 2018-02-20) ↗ |
| FY2015 | Dec 31, 2015 | 7,037 | +1.4% | Form 10-K (filed 2016-02-19) ↗ |
| FY2014 | Dec 31, 2014 | 6,939 | -5.0% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 7,304 | +7.2% | Form 10-K (filed 2014-02-19) ↗ |
| FY2012 | Dec 31, 2012 | 6,811 | +0.1% | Form 10-K (filed 2014-02-19) ↗ |
| FY2011 | Dec 31, 2011 | 6,807 | – | Form 10-K (filed 2014-02-19) ↗ |
Breakdown
What makes up endocrinology therapeutic area — worldwide revenue ($m) [legacy grouping through fy2019]
Cite this data
StockData. (2026). Eli Lilly Endocrinology therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2019] ($M), annual FY2011–FY2017 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_endocrinology_ww_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.